DOCSLIB.ORG

Vulvovaginal Atrophy: a Common—And Commonly Overlooked— Problem Mary H

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vulvovaginal Atrophy: a Common—And Commonly Overlooked— Problem Mary H The Warren Alpert Medical School of Brown University GERI A TRI C S FOR THE Division of Geriatrics PR ac TI C ING PHYSICIAN Quality Partners of RI Department of Medicine EDITED B Y AN A Tuya FU LTON , MD Vulvovaginal Atrophy: A Common—and Commonly Overlooked— Problem Mary H. Hohenhaus, MD, FACP Mrs. K is a 67-year-old woman presenting for a brief All postmenopausal women are at risk for vaginal atrophy. follow-up visit. You treated her for an E. coli urinary Smokers are more estrogen deficient compared with nonsmok- tract infection last month, but she feels well today and ers and may be at higher risk. Engaging in regular sexual activ- offers no complaints. Her blood pressure and lipids ity, whether through intercourse or masturbation, appears to are well controlled on low doses of a single antihyper- decrease risk, possibly through increased blood flow. Women tensive and a lipid lowering agent. She still struggles using anti-estrogen medications, such as aromatase inhibitors with smoking, but has cut down to a few cigarettes a for adjuvant treatment of breast cancer, are more likely to experi- day. She also reports her husband has finally turned ence severe symptoms. over the family business to their children, and they Women may not volunteer symptoms related to vulvovagi- are enjoying spending more time together. When you nal atrophy. The symptomatic woman can experience vaginal ask if there is anything else she needs, she hesitates dryness, burning, and pruritus; yellow, malodorous discharge; for a moment before asking, “Is there anything I can urinary frequency and urgency; and pain during intercourse and do to make sex more comfortable?” bloody spotting afterward. With advanced atrophy, penetration On further questioning, Mrs. K states she and during intercourse may be impossible. Recurrent urinary tract her husband have become more intimate since his infections may occur. retirement, but that attempts at intercourse have Typical findings on external genital exam include sparse been painful and caused bleeding. At times her pubic hair, decreased turgor and elasticity of the vulva, fusion vagina is dry and burns, but at other times there is a of the labia minora, and eversion of the urethral mucosa. The thin yellow discharge. An over-the-counter douche vaginal exam should be approached carefully, with evaluation made the burning worse. A friend suggested an herbal of the width and depth of the introitus before attempting to supplement which she tried for a few weeks without insert a speculum. A narrow Pederson speculum is a better success. She used to enjoy sex but is concerned that choice than the broader Graves speculum. The vaginal exam part of her life “is over for good.” You suspect her shows pale, smooth, shiny mucosa that may be friable and complaints are related to vulvovaginal atrophy. bleed with minimal trauma. The vagina may be dry or there may be watery to serosanguinous discharge. Fissures, diffuse Vulvovaginal atrophy, also known as atrophic vaginitis, results or patchy erythema, petechiae, or visible vessels are common from the decline in endogenous estrogen secretion after meno- findings. Cystocele, rectocele, or uterine prolapse may also pause, which induces thinning of the vulvovaginal epithelium be present. with associated inflammatory changes. It is common in older Vulvovaginal atrophy is primarily a clinical diagnosis in women but not always symptomatic. Unlike vasomotor symp- older women, but select testing can help rule out coexisting toms, which occur early in menopause and usually resolve, vul- conditions suggested by specific symptoms: vovaginal atrophy presents later and is persistent and progressive. True incidence and prevalence are unknown. Estimates suggest • Urinary urgency or frequency: urinalysis and culture to up to half of postmenopausal women are symptomatic, but a rule out urinary tract infection quarter of these will not seek treatment. • Vaginal discharge: microscopy of saline and potassium Estrogen is essential to maintaining the urogenital envi- hydroxide wet preps to evaluate for bacterial vaginosis ronment. After menopause, the vaginal epithelium thins while and vaginal candidiasis subepithelial connective tissue increases, resulting in loss of • Postcoital spotting: cervical cultures or urine testing for rugal folds and elasticity. Vaginal epithelium is a rich source of gonorrhea and chlamydia glycogen, which in turn supports lactic-acid producing bacteria. • Vaginal bleeding: transvaginal ultrasound to evaluate The loss of lactobacilli and subsequent increase in vaginal pH for endometrial overgrowth that accompany estrogen deficiency allows overgrowth of gram • Labial or vaginal wall lesions: biopsy to evaluate for negative rods, which may predispose to urinary tract infection. dermatologic conditions such as lichen planus or ma- Finally, blood flow is reduced, producing a decline in vaginal lignancy secretions. 138 MEDICINE & HEALTH/RHODE ISLAND Table 1. Topical estrogen therapy for vaginal atrophy Whether treatment is needed in asymptomatic women is Estrogen exposure is assumed to be minimized with topi- unknown. Lifestyle modification and over-the-counter vaginal cal therapy, but systemic absorption does occur. Creams have moisturizers and lubricants should be considered as first-line the highest association with systemic absorption, followed by treatment. Women should be counseled to avoid tight-fitting tablets then rings. Safety beyond one year is unknown. Use of clothing, synthetic undergarments, and contact irritants such the lowest effective dose for the shortest duration possible is as scented soaps and feminine hygiene products. Regular use of recommended. vaginal moisturizers (such as Replens) can help relieve vaginal Although endometrial protection is not routinely recom- itching and irritation, while water- or silicone-based personal mended, addition of a cyclic or daily progestin to prevent en- lubricants (such as Astroglide or Eros) during intercourse can dometrial hyperplasia should be considered with long-term or reduce dyspareunia. higher dose (>0.5 mg estradiol or >0.5 g conjugated estrogens/ Estrogen-based treatment restores vaginal epithelium, pH, day) topical therapy. and moisture, and should be considered when non-hormonal Estrogen is contraindicated in known or suspected breast or treatments fail. Although there are few well-designed trials, other estrogen-dependent cancers, undiagnosed vaginal bleeding, topical therapy is preferred for isolated vaginal symptoms given history of thromboembolism, or active thrombophlebitis. Use concern for long-term risks of malignancy and cardiovascular in a woman with breast cancer with severe urogenital atrophy disease with systemic hormone replacement therapy (HRT). unresponsive to non-hormonal treatment should be consid- Local estrogen treatment may also be helpful in women ered only after careful discussion of risks with the woman and taking ultra-low-dose HRT for vasomotor symptoms. If her oncologist. There is additional concern for women using urogenital symptoms are not relieved, the addition of topical adjuvant therapy for breast cancer as there may be sufficient estrogen may limit total estrogen dose compared with use of systemic absorption from topical estrogen to counteract the higher dose HRT. anti-estrogenic effects of aromatase inhibitors. Topical estrogen is available in several forms (see table). Estrogen use should be reviewed every 3 to 6 months, with There are insufficient data to recommend any single treatment an attempt to taper or discontinue its use. Discontinuation often as superior, so patient preference should guide selection. Vaginal results in symptom recurrence. Women using estrogen should symptoms typically respond within a few weeks. Side effects may have an annual clinical breast exam and mammography. Vaginal include breast and perineal pain, local irritation, and endometrial bleeding should prompt transvaginal ultrasound to evaluate for proliferation. endometrial overgrowth, with endometrial biopsy as indicated. 139 VOLUME 94 NO. 5 MAY 2011 The need for surveillance ultrasound in asymptomatic women RESO U R C ES is unknown. North American Menopause Society. The role of local There has been considerable interest in bioidentical hor- vaginal estrogen for treatment of vaginal atrophy in postmeno- mones as well as complementary medications, including phy- pausal women: 2007 position statement of The North American toestrogens, black cohosh, dong quai, ginseng, and red clover, Menopause Society. Menopause 2007;14(3):357-369. but data on their effectiveness are limited. Suckling JA, Kennedy R, Lethaby A, Roberts H. Local Vulvoaginal atrophy is a common, but often unrecognized, oestrogen for vaginal atrophy in postmenopausal women. Co- condition in older women that can significantly affect daily life. chrane Database of Systematic Reviews 2009, Issue 1. Art. No.: Clinicians who care for older women should be alert to possible CD001500. DOI 10.1002/14651858.CD001500.pub2. clues and specifically inquire about symptoms. Effective inter- Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vagi- ventions are available, although more study is needed regarding nal estradiol appears to be contraindicated in postmenopausal the long-term safety of topical estrogens. Given concerns for women on adjuvant aromatase inhibitors. Annals of Oncology systemic effects of topical estrogens, there is significant research 2006;17:584-587. interest in more targeted therapies, such as vaginally delivered Simon
Load more

Recommended publications
  • 3-Year Results of Transvaginal Cystocele Repair with Transobturator Four-Arm Mesh: a Prospective Study of 105 Patients
    Arab Journal of Urology (2014) 12, 275–284 Arab Journal of Urology (Official Journal of the Arab Association of Urology) www.sciencedirect.com ORIGINAL ARTICLE 3-year results of transvaginal cystocele repair with transobturator four-arm mesh: A prospective study of 105 patients Moez Kdous *, Fethi Zhioua Department of Obstetrics and Gynecology, Aziza Othmana Hospital, Tunis, Tunisia Received 27 January 2014, Received in revised form 1 May 2014, Accepted 24 September 2014 Available online 11 November 2014 KEYWORDS Abstract Objectives: To evaluate the long-term efficacy and safety of transobtura- tor four-arm mesh for treating cystoceles. Genital prolapse; Patients and methods: In this prospective study, 105 patients had a cystocele cor- Cystocele; rected between January 2004 and December 2008. All patients had a symptomatic Transvaginal mesh; cystocele of stage P2 according to the Baden–Walker halfway stratification. We Polypropylene mesh used only the transobturator four-arm mesh kit (SurgimeshÒ, Aspide Medical, France). All surgical procedures were carried out by the same experienced surgeon. ABBREVIATIONS The patients’ characteristics and surgical variables were recorded prospectively. The VAS, visual analogue anatomical outcome, as measured by a physical examination and postoperative scale; stratification of prolapse, and functional outcome, as assessed by a questionnaire TOT, transobturator derived from the French equivalents of the Pelvic Floor Distress Inventory, Pelvic tape; Floor Impact Questionnaire and the Pelvic Organ Prolapse–Urinary Incontinence- TVT, tension-free Sexual Questionnaire, were considered as the primary outcome measures. Peri- vaginal tape; and postoperative complications constituted the secondary outcome measures. TAPF, tendinous arch Results: At 36 months after surgery the anatomical success rate (stage 0 or 1) was of the pelvic fascia; 93%.
    [Show full text]
  • Vaginitis and Abnormal Vaginal Bleeding
    UCSF Family Medicine Board Review 2013 Vaginitis and Abnormal • There are no relevant financial relationships with any commercial Vaginal Bleeding interests to disclose Michael Policar, MD, MPH Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine [email protected] Vulvovaginal Symptoms: CDC 2010: Trichomoniasis Differential Diagnosis Screening and Testing Category Condition • Screening indications – Infections Vaginal trichomoniasis (VT) HIV positive women: annually – Bacterial vaginosis (BV) Consider if “at risk”: new/multiple sex partners, history of STI, inconsistent condom use, sex work, IDU Vulvovaginal candidiasis (VVC) • Newer assays Skin Conditions Fungal vulvitis (candida, tinea) – Rapid antigen test: sensitivity, specificity vs. wet mount Contact dermatitis (irritant, allergic) – Aptima TMA T. vaginalis Analyte Specific Reagent (ASR) Vulvar dermatoses (LS, LP, LSC) • Other testing situations – Vulvar intraepithelial neoplasia (VIN) Suspect trich but NaCl slide neg culture or newer assays – Psychogenic Physiologic, psychogenic Pap with trich confirm if low risk • Consider retesting 3 months after treatment Trichomoniasis: Laboratory Tests CDC 2010: Vaginal Trichomoniasis Treatment Test Sensitivity Specificity Cost Comment Aptima TMA +4 (98%) +3 (98%) $$$ NAAT (like GC/Ct) • Recommended regimen Culture +3 (83%) +4 (100%) $$$ Not in most labs – Metronidazole 2 grams PO single dose Point of care – Tinidazole 2 grams PO single dose •Affirm VP III +3 +4 $$$ DNA probe • Alternative regimen (preferred for HIV infected
    [Show full text]
  • Complications of Incontinence and Prolapse Surgery: Evaluation, Intervention, and Resolution—A Review from Both Specialties W42, 16 October 2012 14:00 - 18:00
    Complications of Incontinence and Prolapse Surgery: Evaluation, Intervention, and Resolution—A Review from Both Specialties W42, 16 October 2012 14:00 - 18:00 Start End Topic Speakers 14:00 14:10 Introduction Howard Goldman 14:10 14:35 Complications of incontinence surgery (except Sandip Vasavada retention) 14:35 15:10 Retention/Voiding dysfunction after incontinence Roger Dmochowski surgery 15:10 15:30 Discussion All 15:30 16:00 Break None 16:00 16:35 Complications of prolapse surgery (except Howard Goldman dyspareunia) 16:35 17:00 Dyspareunia after pelvic floor surgery Tristi Muir 17:00 17:40 Discussion All 17:40 18:00 Questions All Aims of course/workshop This course will summarize both common and uncommon complications associated with standard and new technologies used for pelvic floor reconstruction and urinary incontinence therapy in women. The intent of this course is to present both the approach to evaluation and management of these complications from both the urologic and urogynecologic perspective of the combined faculty. The emphasis is on newer technologies and complications, both acute and chronic, which are associated with these various surgeries. The goal of this course will be to summarize, not only identification, but also evaluation and appropriate intervention, as well as patient counselling for these various complications. Educational Objectives This course will provide a detailed paradigm for avoiding, evaluating and managing complications of incontinence and prolapse surgery. Evidence continues to accrue in this area but it runs the spectrum from Level 1 to 5 with much being expert opinion. Unfortunately, very little cross comparison exists to support these differing interventions.
    [Show full text]
  • Pessary Information
    est Ridge obstetrics & gynecology, LLP 3101 West Ridge Road, Rochester, NY 14626 1682 Empire Boulevard, Webster, NY 14580 www.wrog.org Tel. (585) 225‐1580 Fax (585) 225‐2040 Tel. (585) 671‐6790 Fax (585) 671‐1931 USE OF THE PESSARY The pessary is one of the oldest medical devices available. Pessaries remain a useful device for the nonsurgical treatment of a number of gynecologic conditions including pelvic prolapse and stress urinary incontinence. Pelvic Support Defects The pelvic organs including the bladder, uterus, and rectum are held in place by several layers of muscles and strong tissues. Weaknesses in this tissue can lead to pelvic support defects, or prolapse. Multiple vaginal deliveries can weaken the tissues of the pelvic floor. Weakness of the pelvic floor is also more likely in women who have had a hysterectomy or other pelvic surgery, or in women who have conditions that involve repetitive bearing down, such as chronic constipation, chronic coughing or repetitive heavy lifting. Although surgical repair of certain pelvic support defects offers a more permanent solution, some patients may elect to use a pessary as a very reasonable treatment option. Classification of Uterine Prolapse: Uterine prolapse is classified by degree. In first‐degree uterine prolapse, the cervix drops to just above the opening of the vagina. In third‐degree prolapse, or procidentia, the entire uterus is outside of the vaginal opening. Uterine prolapse can be associated with incontinence. Types of Vaginal Prolapse: . Cystocele ‐ refers to the bladder falling down . Rectocele ‐ refers to the rectum falling down . Enterocele ‐ refers to the small intestines falling down .
    [Show full text]
  • ICD-9-CM and ICD-10-CM Codes for Gynecology and Obstetrics
    Diagnostic Services ICD-9-CM and ICD-10-CM Codes for Gynecology and Obstetrics ICD-9 ICD-10 ICD-9 ICD-10 Diagnoses Diagnoses Code Code Code Code Menstral Abnormalities 622.12 Moderate Dysplasia Of Cervix (CIN II) N87.2 625.3 Dysmenorrhea N94.6 Menopause 625.4 Premenstrual Syndrome N94.3 627.1 Postmenopausal Bleeding N95.0 626.0 Amenorrhea N91.2 627.2 Menopausal Symptoms N95.1 626.1 Oligomenorrhea N91.5 627.3 Senile Atrophic Vaginitis N95.2 626.2 Menorrhagia N92.0 627.4 Postsurgical Menopause N95.8 626.4 Irregular Menses N92.6 627.8 Perimenopausal Bleeding N95.8 626.6 Metrorrhagia N92.1 Abnormal Pap Smear Results 626.8 Dysfunctional Uterine Bleeding N93.8 795.00 Abnormal Pap Smear Result, Cervix R87.619 Disorders Of Genital Area 795.01 ASC-US, Cervix R87.610 614.9 Pelvic Inflammatory Disease (PID) N73.9 795.02 ASC-H, Cervix R87.611 616.1 Vaginitis, Unspecified N76.0 795.03 LGSIL, Cervix R87.612 616.2 Bartholin’s Cyst N75.0 795.04 HGSIL, Cervix R87.613 Cervical High-Risk HPV DNA 616.4 Vulvar Abscess N76.4 795.05 R87.810 Test Positive 616.5 Ulcer Of Vulva N76.6 Unsatisfactory Cervical 795.08 R87.615 616.89 Vaginal Ulcer N76.5 Cytology Sample 623.1 Leukoplakia Of Vagina N89.4 795.10 Abnormal Pap Smear Result, Vagina R87.628 Vaginal High-Risk HPV DNA 623.5 Vaginal Discharge N89.8 795.15 R87.811 Test Positive 623.8 Vaginal Bleeding N93.9 Disorders Of Uterus And Ovary 623.8 Vaginal Cyst N89.8 218.9 Uterine Fibroid/Leiomyoma D25.9 Noninflammatory Disorder 623.9 N89.9 Of Vagina 256.39 Ovarian Failure E28.39 624.8 Vulvar Lesion N90.89 256.9 Ovarian
    [Show full text]
  • Legacy Health
    Legacy Health Co-Management and Referral Guidelines Management of Pelvic Floor Dysfunction Phone: 503-413-3707 Legacy Physical Therapy Fax: 503-413-1504 Introduction After appropriate evaluation by your care providers, patients may be referred to pelvic floor physical therapy for management of pelvic floor muscle dysfunctions/pain, incontinence of urine or fecal matter, pelvic floor/girdle physical therapy. • Hypertonic pelvic floor dysfunction — vaginismus, dyspareunia, levator ani syndrome • Hypotonic pelvic floor muscles — organ prolapse, rectus diastasis • Continence issues after abdominal surgeries in male and female (prostate or hysterectomies), overactive bladder • Endometriosis, pelvic pain • Chronic constipation Evaluation Evaluation and A careful history and evaluation/physical exam will be performed to assess the origin and functional Management limitations of the patient. Muscle tone assessment, organ mobility, scar tissue mobility, bladder and/or bowel diary Treatment Strengthening or down-training PF muscles, with or without biofeedback, manual therapy, scar tissue release, electrical stimulation, trigger point release, visceral and myofascial mobilization, body mechanics and core stabilization. Duration One to six 60-minute visits with the physical therapist When to refer Refer when pain is limiting normal activities of daily living, if patient is not able to get to the bathroom dry, if sexual activity is painful (although dyspareunia alone is often not covered by insurance) Commonly referred ICD10 codes and descriptors for PT diagnoses R10.9 Abdominal pain K59.4 Anal spasm/proctalgia fugax R39.89 Bladder pain M53.3 Coccygodynia K59.00 Constipation, unspecified N81.10 Cystocele, unspecified (prolapse of anterior vaginal wall NOS) M62.0 Diastasis rectus post-partum N94.1 Dyspareunia — excludes psychogenic dyspareunia (F52.6).
    [Show full text]
  • How to Evaluate Vaginal Bleeding and Discharge
    How to Evaluate Vaginal Bleeding and Discharge Is the bleeding normal or abnormal? When does vaginal discharge reflect something as innocuous as irritation caused by a new soap? And when does it signal something more serious? The authors’ discussion of eight actual patient presentations will help you through the next differential diagnosis for a woman with vulvovaginal complaints. By Vincent Ball, MD, MAJ, USA, Diane Devita, MD, FACEP, LTC, USA, and Warren Johnson, MD, CPT, USA bnormal vaginal bleeding or discharge is typically due to either inadequate levels of estrogen one of the most common reasons women or a persistent corpus luteum. Structural causes of come to the emergency department.1,2 bleeding include leiomyomas, endometrial polyps, or Because the possible underlying causes malignancy. Infectious etiologies include pelvic in- Aare diverse, the patient’s age, key historical factors, flammatory disease (PID). Additionally, a variety of and a directed physical examination are instrumental bleeding dyscrasias involving platelet or clotting fac- in deciding on diagnosis and treatment. This article tors can complicate the normal menstrual period. Iat- will review some common case presentations of rogenic causes of vaginal bleeding include hormone nonpregnant female patients with abnormal vaginal replacement therapy, steroid hormone contraception, bleeding, inflammation, or discharge. and contraceptive intrauterine devices.3-5 Anovulatory bleeding is common in perimenar- ABNORMAL VAGINAL BLEEDING chal girls as a result of an immature hypothalamic- To ensure appropriate patient management, “Is she pituitary axis and in perimenopausal women due to pregnant?” should be the first question addressed, declining levels of estrogen. During reproductive since some vulvovaginal signs and symptoms will years, dysfunctional uterine differ in significance and urgency depending on the bleeding (DUB) is the most >>FAST TRACK<< answer.
    [Show full text]
  • Pelvic Floor Ultrasound in Prolapse: What's in It for the Surgeon?
    Int Urogynecol J (2011) 22:1221–1232 DOI 10.1007/s00192-011-1459-3 REVIEW ARTICLE Pelvic floor ultrasound in prolapse: what’s in it for the surgeon? Hans Peter Dietz Received: 1 March 2011 /Accepted: 10 May 2011 /Published online: 9 June 2011 # The International Urogynecological Association 2011 Abstract Pelvic reconstructive surgeons have suspected technique became an obvious alternative, whether via the for over a century that childbirth-related trauma plays a transperineal [4, 5] (see Fig. 1) or the vaginal route [6]. major role in the aetiology of female pelvic organ prolapse. More recently, magnetic resonance imaging has also Modern imaging has recently allowed us to define and developed as an option [7], although the difficulty of reliably diagnose some of this trauma. As a result, imaging obtaining functional information, and cost and access is becoming increasingly important, since it allows us to problems, have hampered its general acceptance. identify patients at high risk of recurrence, and to define Clinical examination techniques, in particular if the underlying problems rather than just surface anatomy. examiner is insufficiently aware of their inherent short- Ultrasound is the most appropriate form of imaging in comings, are rather inadequate tools with which to assess urogynecology for reasons of cost, access and performance, pelvic floor function and anatomy. This is true even if one and due to the fact that it provides information in real time. uses the most sophisticated system currently available, the I will outline the main uses of this technology in pelvic prolapse quantification system of the International Conti- reconstructive surgery and focus on areas in which the nence Society (ICS Pelvic Organ Prolapse Quantification benefit to patients and clinicians is most evident.
    [Show full text]
  • The Effects of a Life-Stress Interview for Women with Chronic Urogenital Pain: a Randomized Trial" (2016)
    Wayne State University Wayne State University Dissertations 1-1-2016 The ffecE ts Of A Life-Stress Interview For Women With Chronic Urogenital Pain: A Randomized Trial Jennifer Carty Wayne State University, Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations Part of the Clinical Psychology Commons Recommended Citation Carty, Jennifer, "The Effects Of A Life-Stress Interview For Women With Chronic Urogenital Pain: A Randomized Trial" (2016). Wayne State University Dissertations. Paper 1521. This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. THE EFFECTS OF A LIFE-STRESS INTERVIEW FOR WOMEN WITH CHORNIC UROGENITAL PAIN: A RANDOMIZED TRAIL by JENNIFER N. CARTY DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2016 MAJOR: PSYCHOLOGY (Clinical) Approved By: ______________________________ Advisor Date ______________________________ ______________________________ ______________________________ ACKNOWLEDGEMENTS I am immensely grateful to many people for their contributions to this project and my professional and personal development. First, I would like to thank my advisor, Dr. Mark Lumley, for his guidance and support in the development of this project, and for both encouraging and challenging me throughout my academic career, for which I will always be grateful. I would also like to thank Dr. Janice Tomakowsky, Dr. Kenneth Peters, and the medical providers, physical therapists, and staff at the Women’s Urology Center at Beaumont Hospital for graciously allowing me to conduct this study at their clinic and with their patients.
    [Show full text]
  • Uro 2018-159 Issue Date: 02/2015 Review Date: 03/2021 © Liverpool Women’S NHS Foundation Trust
    Vaginal Pessary Information Leaflet What Is A Pessary? A pessary is a plastic or silicone device that fits into your vagina to support a prolapsed bladder, rectum or uterus (womb). There are different types but the most commonly used are either a ring or a shelf pessary. 71%- 90% of women are successfully fitted with a pessary. What Is A Prolapse? A prolapse means that your uterus, bladder or rectum is bulging or leaning into the vagina, because the muscular walls of the vagina have become weakened. This can sometimes be felt as a lump in the vagina. If the prolapse is large it may also cause difficulty when emptying the bladder or bowel. It is possible for women to have more than one type of prolapse. 50% of women can get a prolapse. Patients can have varying symptoms such as vaginal heaviness, pelvic pressure bulging into the vagina and backache. What Are The Different Types Of Prolapse? Cystocele A cystocele occurs when the vaginal wall that is next to the bladder becomes weakened. This causes the bladder to lean (or prolapse) into the vagina, where it may then be felt as a lump (See Figure 1) Cystocele Figure 1 Rectocele A rectocele occurs when the vaginal wall next to the rectum becomes weakened. This causes the rectum to lean (or prolapse) into the vagina, where it may then be felt as a lump. This type of prolapse may cause difficulty when opening your bowels. (See Figure 2) Figure 2 Uterine prolapse A Uterine prolapse occurs when the structures that support the womb weaken.
    [Show full text]
  • Vaginal Atrophy (VVA)
    Information Sheet Vulvovaginal symptoms after menopause Key points • Vulvovaginal symptoms are numerous and varied and result from declining oestrogen levels. • Investigate any post- menopausal bleeding or malodorous discharge. • Management includes lifestyle changes as well as prescription and non- prescription medications. • As women age they will experience changes to their vagina and urinary system largely due to decreasing levels of the hormone oestrogen. • The changes, which may cause dryness, irritation, itching and pain with intercourse1-3 are known as the genito-urinary syndrome of menopause (GSM) and can affect up to 50% of postmenopausal women4. GSM was previously known as atrophic vaginitis or vulvovaginal atrophy (VVA). • Unlike some menopausal symptoms, such as hot flushes, which may disappear as time passes; genito-urinary problems often persist and may progress with time. Genito-urinary symptoms are associated both with menopause and with ageing4. • Changes in vaginal and urethral health occur with natural and surgical menopause, as well as after treatments for certain medical conditions (Please refer to AMS Information Sheet Vaginal health after breast cancer: A guide for patients). Why is oestrogen important for vaginal health? • The vaginal area needs adequate levels of oestrogen to maintain tissue integrity. • The vaginal epithelium contains oestrogen receptors which, when stimulated by the hormone, keep the walls thick and elastic. • When the amount of oestrogen in the body decreases this is commonly associated with dryness of the vulva and vagina. • A normal pre-menopausal vagina is naturally acidic, but with menopause it may become more alkaline, increasing susceptibility to urinary tract infections. A number of factors, including low oestrogen levels, have been implicated in the development of UTIs4-7 and vaginitis8-9 in postmenopausal women.
    [Show full text]
  • The Woman with Postmenopausal Bleeding
    THEME Gynaecological malignancies The woman with postmenopausal bleeding Alison H Brand MD, FRCS(C), FRANZCOG, CGO, BACKGROUND is a certified gynaecological Postmenopausal bleeding is a common complaint from women seen in general practice. oncologist, Westmead Hospital, New South Wales. OBJECTIVE [email protected]. This article outlines a general approach to such patients and discusses the diagnostic possibilities and their edu.au management. DISCUSSION The most common cause of postmenopausal bleeding is atrophic vaginitis or endometritis. However, as 10% of women with postmenopausal bleeding will be found to have endometrial cancer, all patients must be properly assessed to rule out the diagnosis of malignancy. Most women with endometrial cancer will be diagnosed with early stage disease when the prognosis is excellent as postmenopausal bleeding is an early warning sign that leads women to seek medical advice. Postmenopausal bleeding (PMB) is defined as bleeding • cancer of the uterus, cervix, or vagina (Table 1). that occurs after 1 year of amenorrhea in a woman Endometrial or vaginal atrophy is the most common cause who is not receiving hormone therapy (HT). Women of PMB but more sinister causes of the bleeding such on continuous progesterone and oestrogen hormone as carcinoma must first be ruled out. Patients at risk for therapy can expect to have irregular vaginal bleeding, endometrial cancer are those who are obese, diabetic and/ especially for the first 6 months. This bleeding should or hypertensive, nulliparous, on exogenous oestrogens cease after 1 year. Women on oestrogen and cyclical (including tamoxifen) or those who experience late progesterone should have a regular withdrawal bleeding menopause1 (Table 2).
    [Show full text]